IHC could be a pre-screening and supplementary algorithm to provide more clues for clinical trial design and therapeutic strategies for NSCLC patients harboring ALK rearrangement, including patients with double genetic aberration of ALK and EGFR. However, the true prognostic value of ALK expression should be further validated in future prospective studies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.